As one of the most studied synthetic drugs in modern history, quinacrine HCI was first used as an antimalarial and later to treat rheumatic skin diseases, including lupus. With May designated as Lupus Awareness month, learn more about quinacrine HCI and the twists and turns of its storied past.

Menopause causes more than hot flashes, mood swing and changes in libido; it also impacts diseases caused by shifting changes in the vaginal microbiome. Bridget Briggs, MD, sheds light on the vaginal microbiome, its influences on a woman’s health throughout various life stages, as well as how HRT helps mediate changes — and associated diseases — in the vaginal microbiome during menopause.

In today's fast-paced world, maintaining optimal health can be a challenge. Despite the best intentions, many adults struggle to meet their nutritional needs through diet alone — that's where supplements can play a crucial role.

Dr. Loyd V. Allen, Jr., PhD, RPh, FACA, a trailblazer in the compounding industry who was highly regarded by students, colleagues and regulatory agencies, passed away on April 23, 2024.

In recognition of National Infertility Awareness Week, April 21-27, PCCA Director of Clinical Services Sara Hover, RPh, FAARM, discusses how fertility is increasingly viewed as an indicator of overall health; how the intertwine of metabolic balance, hormone production and mitochondria impact fertility; as well as a way compounders can help those whose individual needs exceed commercially available medicines.

Compounding pharmacists are committed to helping their patients live healthier, better lives —and key to this is ensuring their patients have continuing access to lawfully prescribed, personalized medications tailored to their individual needs.

Our Profiles in Personalized Medicine highlights Matthew McLachlan, BPharm, MPS, co-owner of O’Hara's Pharmacy 777 Kalamunda in Kalamunda, Western Australia. Matthew shares what motivated him to become a compounding pharmacist, how his pharmacy promotes compounding in their community and more. He and co-owner Andrew Mason, BPharm, MPS, have been proud PCCA members since 2018.

In February, the FDA approved the first and only oral treatment for eosinophilic esophagitis (EoE) that contains the active pharmaceutical ingredient (API) budesonide at a strength of 2 mg/10mL, which may sound familiar to many compounders.1 How does this affect compounders and what other potential options are available to patients?

The PCCA Research & Development (R&D) team constantly explores innovative ways to help meet the unique needs of patients. Using a multi-disciplinary approach, we developed SubMagna SL HMW, a self-emulsifying, sublingual delivery system, to accommodate a wide range of drugs with varying molecular weights — including those with a high-molecular weight. This innovative base is another way PCCA helps to fill the unmet needs of patients, prescribers and compounding pharmacies.

Our Profiles in Personalized Medicine highlights Isha Gupta, PharmD, MBA, owner of HatchRx Compounding Pharmacy in Long Island, New York. Isha shares her perspectives on what “Compounding: It’s Personal” means, what motivated her to become a compounding pharmacist, as well as a patient success story and more. Her pharmacy has been a proud PCCA member since 2022.